163 related articles for article (PubMed ID: 37921919)
1. A Prospective Longitudinal Study of the Effects of Eslicarbazepine Acetate Treatment on Bone Density and Metabolism in Patients with Focal-Onset Epilepsy.
Hirsch M; Immisch I; Knake S; Schulze-Bonhage A
CNS Drugs; 2023 Nov; 37(11):973-980. PubMed ID: 37921919
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: Case series.
Gómez-Ibáñez A; Serratosa JM; Guillamón E; Garcés M; Giráldez BG; Toledo M; Salas-Puig J; López-González FJ; Rodríguez-Uranga J; Castillo A; Mauri JA; Camacho JL; López-Gomáriz E; Giner P; Torres N; Palau J; Molins A; Villanueva V
Seizure; 2017 May; 48():53-56. PubMed ID: 28419947
[TBL] [Abstract][Full Text] [Related]
3. Eslicarbazepine acetate add-on therapy for drug-resistant focal epilepsy.
Chang XC; Yuan H; Wang Y; Xu HQ; Hong WK; Zheng RY
Cochrane Database Syst Rev; 2021 Jun; 6(6):CD008907. PubMed ID: 34155624
[TBL] [Abstract][Full Text] [Related]
4. EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first monotherapy failure.
Villanueva V; Bermejo P; Montoya J; Toledo M; Gómez-Ibáñez A; Garcés M; Vilella L; López-González FJ; Rodriguez-Osorio X; Campos D; Martínez P; Giner P; Zurita J; Rodríguez-Uranga J; Ojeda J; Mauri JA; Camacho JL; Ruiz-Giménez J; Poza JJ; Massot-Tarrús A; Galiano ML; Bonet M
Acta Neurol Scand; 2017 Sep; 136(3):254-264. PubMed ID: 27935017
[TBL] [Abstract][Full Text] [Related]
5. [Eslicarbazepine acetate in clinical practice. Efficacy and safety results].
Serrano-Castro PJ; Payán-Ortiz M; Cimadevilla JM; Quiroga-Subirana P; Fernández-Pérez J
Rev Neurol; 2013 Mar; 56(6):309-14. PubMed ID: 23483464
[TBL] [Abstract][Full Text] [Related]
6. Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study.
Correia FD; Freitas J; Magalhães R; Lopes J; Ramalheira J; Lopes-Lima J; Chaves J
Epilepsy Res; 2014 Oct; 108(8):1399-405. PubMed ID: 25060997
[TBL] [Abstract][Full Text] [Related]
7. Serum sodium levels and related treatment-emergent adverse events during eslicarbazepine acetate use in adults with epilepsy.
Wechsler RT; Radtke RA; Smith M; Vossler DG; Strom L; Trinka E; Cheng H; Grinnell T; Blum D; Vieira M; Moreira J; Rocha F
Epilepsia; 2019 Jul; 60(7):1341-1352. PubMed ID: 31260089
[TBL] [Abstract][Full Text] [Related]
8. Time to baseline seizure count in patients with focal seizures receiving adjunctive eslicarbazepine acetate in a phase IV clinical trial.
Aboumatar S; Krishnaiengar SR; Cantu D; Zhang Y; Grinnell T
Clin Neurol Neurosurg; 2023 Feb; 225():107552. PubMed ID: 36657359
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study.
Trinka E; Rocamora R; Chaves J; Moreira J; Ikedo F; Soares-da-Silva P;
Epilepsia; 2020 Oct; 61(10):2129-2141. PubMed ID: 32944934
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with eslicarbazepine acetate in adults with sub-analysis of elderly.
Nielsen MK; Petrenaite V; Andersen NB
Seizure; 2017 Dec; 53():94-99. PubMed ID: 29172139
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: Results of an indirect comparison meta-analysis of RCTs.
Brigo F; Bragazzi NL; Nardone R; Trinka E
Seizure; 2016 Nov; 42():29-37. PubMed ID: 27710868
[TBL] [Abstract][Full Text] [Related]
12. Eslicarbazepine acetate as adjunctive treatment in partial-onset epilepsy.
Lattanzi S; Cagnetti C; Foschi N; Lorusso A; Provinciali L; Silvestrini M
Acta Neurol Scand; 2018 Jan; 137(1):29-32. PubMed ID: 28741673
[TBL] [Abstract][Full Text] [Related]
13. Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.
Shorvon SD; Trinka E; Steinhoff BJ; Holtkamp M; Villanueva V; Peltola J; Ben-Menachem E
J Neurol; 2017 Mar; 264(3):421-431. PubMed ID: 28101651
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy.
Banach M; Borowicz KK; Czuczwar SJ
Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):639-48. PubMed ID: 25740561
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial.
Kirkham F; Auvin S; Moreira J; Gama H; Falcão AC; Rocha JF; Soares-da-Silva P
Epilepsy Behav; 2020 Apr; 105():106962. PubMed ID: 32151803
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures.
Chung S; Sinha SR; Shah A; Stern JM; Cheng H; Jung J; Grinnell T; Blum D
Epilepsy Res; 2019 Jul; 153():59-65. PubMed ID: 30999260
[TBL] [Abstract][Full Text] [Related]
17. Eslicarbazepine acetate as adjunctive therapy in clinical practice: ESLADOBA study.
Chaves J; Breia P; Pimentel J; Pelejão R; Carvalho M; Mateus P; Grebe H; Mestre A; Fernandes H; Sousa R; Gala A
Acta Neurol Scand; 2017 Nov; 136(5):407-413. PubMed ID: 28181220
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice.
Rocamora R; Peltola J; Assenza G; McMurray R; Villanueva V
Seizure; 2020 Feb; 75():121-128. PubMed ID: 31981862
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study.
Toledano R; Jovel CE; Jiménez-Huete A; Bayarri PG; Campos D; Gomariz EL; Giráldez BG; García-Morales I; Falip M; Agredano PM; Palao S; Prior MJAA; Pascual MRQ; Navacerrada FJ; González FJL; Ojeda J; Sáez AA; Bermejo PE; Gil-Nagel A
Epilepsy Behav; 2017 Aug; 73():173-179. PubMed ID: 28641170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
